Management of Atrial Fibrillation with Rapid Ventricular Response

Initial Management

The American College of Cardiology recommends immediate assessment of hemodynamic stability and performance of urgent direct-current cardioversion if the patient has symptomatic hypotension, ongoing angina, heart failure, or hemodynamic compromise 1, 2
Target ventricular rate should be 60-80 beats per minute at rest and 90-115 beats per minute during moderate exercise, according to the American College of Cardiology 1, 2

Combination therapy may be necessary when single agents fail to achieve adequate rate control, as suggested by the American College of Cardiology 1, 2, 3
The American College of Cardiology advises against administering AV nodal blocking agents in patients with Wolff-Parkinson-White syndrome and pre-excitation, as these can cause acceleration of ventricular rate, hypotension, or ventricular fibrillation 1, 2, 3

For hemodynamically stable Wolff-Parkinson-White patients, the American College of Cardiology recommends administering intravenous procainamide or amiodarone 1, 3
For hemodynamically unstable Wolff-Parkinson-White patients, the American College of Cardiology suggests performing immediate direct-current cardioversion 1, 3
The European Heart Journal recommends considering elective direct-current cardioversion for symptomatic patients who remain symptomatic despite rate control or when rate control is inadequate 4

Sustained uncontrolled tachycardia can cause tachycardia-induced cardiomyopathy, which typically resolves within 6 months of adequate rate or rhythm control, according to the American College of Cardiology 1, 2, 3
The American College of Cardiology suggests considering AV nodal ablation with pacemaker implantation for refractory cases when pharmacological measures fail 1, 2

The American College of Cardiology advises monitoring heart rate during exercise, as rates may be well-controlled at rest but accelerate excessively with activity 1, 3
Bradycardia and heart block can occur with rate-controlling medications, particularly in elderly patients with paroxysmal AF, as noted by the American College of Cardiology 1, 2, 3
In patients with atrial flutter and AF, the American College of Cardiology recommends co-administering AV nodal blocking drugs when using antiarrhythmic agents to prevent 1:1 AV conduction and very rapid ventricular response 2, 3

The American Heart Association recommends evaluating hemodynamic stability, including presence of hypotension, ongoing ischemia, or inadequate rate control, which requires urgent intervention 5
The American College of Cardiology suggests identifying potential underlying causes of AF with RVR, including thyrotoxicosis, pulmonary disease, acute coronary syndrome, or Wolff-Parkinson-White syndrome, to guide management 6
Assess for presence of structural heart disease, particularly left ventricular dysfunction, which will guide medication selection, as recommended by the American Heart Association 5

For patients with preserved ejection fraction (LVEF >40%), the American Heart Association recommends intravenous beta-blockers (e.g., metoprolol) or non-dihydropyridine calcium channel blockers (diltiazem, verapamil) as first-line therapy 5, 7
For patients with reduced ejection fraction (LVEF ≤40%), the American College of Cardiology suggests intravenous beta-blockers, and considers digoxin in combination with beta-blockers for enhanced rate control 6, 7
In special situations, such as acute coronary syndrome, thyrotoxicosis, or chronic obstructive pulmonary disease, specific rate control strategies are recommended, including intravenous beta-blockers, non-dihydropyridine calcium channel antagonists, or avoidance of certain medications, as suggested by the European Heart Journal and the Journal of the American College of Cardiology 5, 8, 9

The American Heart Association recommends assessing stroke risk using the CHA₂DS₂-VASc score, and anticoagulation with warfarin or direct oral anticoagulants for patients with CHA₂DS₂-VASc score ≥2 5, 6
Continue anticoagulation for at least 4 weeks after cardioversion in patients with stroke risk factors, as suggested by the American College of Cardiology 6, 7

Elective direct-current cardioversion may be considered for patients with symptomatic AF, as recommended by the European Heart Journal 8
For patients with AF duration >48 hours or unknown duration, ensure therapeutic anticoagulation for at least 3 weeks before cardioversion or perform transesophageal echocardiography to exclude left atrial thrombus, as suggested by the American College of Cardiology 6, 7